Abstract:The rebound competent viral reservoir (RCVR)–virus that persists during antiretroviral treatment (ART) and can reignite systemic infection when treatment is stopped–is the primary barrier to eradicating HIV. We used time to initiation of ART during primary infection of rhesus macaques (RMs) after intravenous challenge with barcoded SIVmac239 as a means to elucidate the dynamics of RCVR establishment in groups of RMs by creating a multi-log range of pre-ART viral loads and then assessed viral time-to-rebound and reactivation rates resulting from the discontinuation of ART after one year. RMs started on ART on days 3, 4, 5, 6, 7, 9 or 12 post-infection showed a nearly 10-fold difference in pre-ART viral measurements for successive ART-initiation timepoints. Only 1 of 8 RMs initiating ART on days 3 and 4 rebounded after ART interruption despite measurable pre-ART plasma viremia. Rebounding plasma from the 1 rebounding RM contained only a single barcode lineage detected at day 50 post-ART. All RMs starting ART on days 5 and 6 rebounded between 14- and 50-days post-ART with 1–2 rebounding variants each. RMs starting ART on days 7, 9, and 12 had similar time-to-measurable plasma rebound kinetics despite multiple log differences in pre-ART plasma viral load (pVL), with all RMs rebounding between 7- and 16-days post-ART with 3–28 rebounding lineages. Calculated reactivation rates per pre-ART pVL were highest for RMs starting ART on days 5, 6, and 7 after which the rate of accumulation of the RCVR markedly decreased for RMs treated on days 9 and 12, consistent with multiphasic establishment and near saturation of the RCVR within 2 weeks post infection. Taken together, these data highlight the heterogeneity of the RCVR between RMs, the stochastic establishment of the very early RCVR, and the saturability of the RCVR prior to peak viral infection. Antiretroviral therapy (ART) stops HIV replication without impacting the "rebound-competent viral reservoir" (RCVR), comprised of persistent, already infected cells that can rekindle active HIV infection once ART is stopped. Despite much effort, the characteristics of the clinically relevant RCVR remain poorly defined. We developed a SIV-infected rhesus macaque model and studied temporal development of the RCVR during primary SIV infection, characterizing the impact of RCVR establishment dynamics on post-ART SIV rebound dynamics. Despite measurable SIV viremia, the viral dissemination that developed up to day 4 of SIV infection was highly labile, unable to form an RCVR that can mediate viral rebound after discontinuation of one year of ART. From days 5 to 7, both the extent of primary infection assessed by plasma viremia and post-ART viral reactivation rates exponentially increased in concert, but from day 7 to 12 post-infection, reactivation rates only marginally increased whereas extent of infection continued exponential expansion. This disconnect suggests that the multiphase establishment of the RCVR is saturable and therefore constitutes only a subset of overall SIV infection when ART is initiated after day 7. These observations have important implications for therapeutic targeting of the RCVR and for measuring the impact of such therapies on RCVR size in vivo .

Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

Dynamic Decay of Viral Reservoirs in Systemic and Lymphoid Compartments of SIV-infected Rhesus Macaques on Long-Term Combined Antiretroviral Therapy

Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques

Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART

Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption

Comparative Analysis of Within-Host Dynamics of Acute Infection and Viral Rebound Dynamics in Postnatally SHIV-Infected ART-Treated Infant Rhesus Macaques

Assessing the impact of autologous neutralizing antibodies on rebound dynamics in postnatally SHIV-infected ART-treated infant Rhesus macaques

Assessing the impact of autologous neutralizing antibodies on viral rebound in postnatally SHIV-infected ART-treated infant rhesus macaques

Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

Quantifying integrated SIV-DNA by repetitive-sampling Alu-gag PCR

Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques

Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection

Rapid Clearance of Simian Immunodeficiency Virus Particles from Plasma of Rhesus Macaques.